Effect of the SCOT-HEART 2 Trial on Lifestyle.

Sponsor
University of Edinburgh (Other)
Overall Status
Recruiting
CT.gov ID
NCT04156061
Collaborator
British Heart Foundation (Other), NHS Lothian (Other)
400
1
3
35
11.4

Study Details

Study Description

Brief Summary

This study will recruit 400 participants who are taking part in the Computed Tomography Coronary Angiography for the Prevention of Myocardial Infarction (SCOT-HEART 2) trial. The investigator will assess diet, activity and habits at the start of the study and 6 months later. This will help us understand the effects taking part in the study may have on lifestyle. In addition, for participants who have CT scans, the investigator will present the results of the heart from the CT scan. This will help us understand how best to explain the results of the CT scan to patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Delivery of CT scan results
N/A

Detailed Description

This is a sub-study of the SCOT-HEART 2 trial (which aims to determine the best way to prevent heart attacks).

The purpose of this sub-study is to determine the effect of getting information on heart disease risk on lifestyle. At present doctors usually use a "risk score" to identify people at risk of heart disease who may benefit from medical treatment. In the SCOT-HEART 2 study the investigator will compare this "risk score" to a specialised heart scan (a computed tomography coronary angiogram or CTCA scan). In this study the investigator would like to understand more about the effects of receiving this information about the heart on lifestyle, including effects on smoking, diet and activity.

This study will recruit 400 participants who are taking part in the SCOT-HEART 2 trial. The investigator will assess lifestyle by using a detailed questionnaire which will be done at the start of the study and 6 months later. The investigator will also perform some simple investigations including a carbon monoxide breath test, blood pressure tests and measurements of activity such as step counts. This will help us understand the effects on lifestyle of getting information about a "risk score" or having a CT scan. In addition, for people who have CT scans the investigator will either provide a verbal explanation of the results, as is usual, or show pictures of the heart from the CT scan. This will help us understand how best to explain the results of the CT scan to partipants.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Effect of the SCOT-HEART 2 Trial on Lifestyle and Risk Factor Modification.
Actual Study Start Date :
Sep 28, 2020
Anticipated Primary Completion Date :
Apr 30, 2022
Anticipated Study Completion Date :
Aug 30, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: ASSIGN score

The baseline assessment will be completed on the same day as consent is gained. Every patients will complete a comprehensive assessment including questionnaires and objective assessments. Patients randomised to standard care with ASSIGN score alone (n=200) will be invited back approximately 6 months after baseline assessment. The detailed questionnaire, breath test, blood pressure monitoring, and 2-week activity monitor will be repeated. Bloods will be retaken to look at change in lipid levels and HbA1c where appropriate - no more than 30mls will be required.

Active Comparator: CTCA - visual report

Those in the CTCA group will be further randomised into review with or without CT images. The review WITH images (VISUAL REPORT N=100) group will have results delivered by the principal investigator (a trained Cardiology Registrar) to ensure a standardised approach to relaying information. These results will be preliminary and focused only on whether the patient has evidence of coronary disease or not. A full report describing the extent of coronary disease, other cardiac problems and incidental findings will follow as per the SCOT-HEART-2 protocol. Patients will be made aware that the presented findings are a focused preliminary report and that a more detailed formal report will follow.

Other: Delivery of CT scan results
Method of results delivery - verbal or visual.

Active Comparator: CTCA - verbal report

The baseline assessment will be completed on the same day as consent is gained. Every patients will complete a comprehensive assessment including questionnaires and objective assessments. Those in the CTCA group will be further randomised into review with or without CT images. The review WITHOUT images (VERBAL REPORT N=100) group will have results delivered by the principal investigator (a trained Cardiology Registrar) to ensure a standardised approach to relaying information. These results will be preliminary and focused only on whether the patient has evidence of coronary disease or not. A full report describing the extent of coronary disease, other cardiac problems and incidental findings will follow as per the SCOT-HEART-2 protocol. Patients will be made aware that the presented findings are a focused preliminary report and that a more detailed formal report will follow.

Other: Delivery of CT scan results
Method of results delivery - verbal or visual.

Outcome Measures

Primary Outcome Measures

  1. Proportion of patients who meet National Institute for Heath and Care Excellence (NICE) recommendations on risk factor modifications [6 months]

    The primary endpoint will be the proportion of patients who meet NICE recommendations on diet, smoking, weight and activity levels (%)

Secondary Outcome Measures

  1. Smoking cessation [6 months]

    Proportion of patients who changed smoking habits (%)

  2. Weight loss [6 months]

    Measure change in weight via body mass index and waist circumference (%)

  3. Blood pressure control [6 months]

    Change in blood pressure control through lifestyle/compliance with medications (%)

  4. Lipid levels [6 months]

    Change in serum lipid levels through lifestyle/compliace with medications (%)

  5. Diabetic control [6 months]

    Change in glycosylated haemoglobin (HbA1c) (%)

  6. Adherence to medications [6 months]

    Change in compliance with medications tracked through questionnaire

  7. Exercise [6 months]

    Change in activity levels measured through activity monitoring (step count over 2 weeks) and international physical activity questionnaire

  8. Quality of life/Anxiety and Depression [6 months]

    Change in quality of life measured through PHQ-9 (patient health questionnaire): anxiety and depression score (%)

  9. ASSIGN score [6 months]

    Change in ASSIGN score as a result of lifestyle / risk factor modification (%)

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • MUST BE ENROLLED IN SCOTHEART 2 TRIAL
Exclusion Criteria:
  • MUST BE ENROLLED IN SCOTHEART 2 TRIAL

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Edinburgh Edinburgh Midlothian United Kingdom EH16 4SB

Sponsors and Collaborators

  • University of Edinburgh
  • British Heart Foundation
  • NHS Lothian

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Edinburgh
ClinicalTrials.gov Identifier:
NCT04156061
Other Study ID Numbers:
  • AC19113
First Posted:
Nov 7, 2019
Last Update Posted:
Oct 6, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 6, 2021